Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for severe and treatment-resistant depression
IRCT20230618058520N1Phase 2Completed
- Sponsor
- Shahrood Islamic Azad University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Shahrood Islamic Azad University. Started Jul 2023; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20230618058520N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230618058520N1.